High demand for weight-loss and diabetes drugs like Ozempic and Wegovy has led to a shortage in manufacturing. In the meantime, a market for cheaper, compounded drugs thrives.

Researchers from the University of Liverpool have found that the weight-loss drug tirzepatide could significantly reduce the risk of developing type 2 diabetes (T2D). This finding offers new hope in the battle against obesity and diabetes,

Amycretin, an oral weight loss drug, led to up to 13% body weight reduction in three months, showing potential for continued weight loss. While well-tolerated, further long-term studies are needed to evaluate its safety and efficacy.

The manufacturer of Ozempic is testing amycretin, an experimental weight-loss pill that appears to help people quickly shed pounds.

In a society that has so many people who are overweight, it is understandable there’s such a craze for new drugs that are helping people to lose weight. Drugs like Ozempic and Wegovy were developed for people with diabetes but have proven to be great resources for losing weight.

Novo Nordisk and Eli Lilly are offering discounts to encourage more insurance coverage of the medicines, which carry price tags of over $1,000 a month.

F ROM LOS ANGELES to London, weight-loss drugs such as Ozempic are reshaping culture as much as waistlines. Some Ozempic-takers have tiny appetites and dine at unusual hours to avoid spells of nausea.

Weight-loss drugs like Ozempic are booming in popularity, but experts warn they aren't silver bullets for obesity.